<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5588">
  <stage>Registered</stage>
  <submitdate>31/05/2011</submitdate>
  <approvaldate>31/05/2011</approvaldate>
  <nctid>NCT01363999</nctid>
  <trial_identification>
    <studytitle>A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers</studytitle>
    <scientifictitle>A Single-center, Randomized, Open-label, Four Treatments, Four Periods, Four Sequence, Four-way Crossover Study to Explore the Pharmacokinetic Performance of Dalcetrapib and Atorvastatin Fixed Dose Combination Prototype Formulations in Healthy Volunteers</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>WP25642</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy Volunteer</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - atorvastatin
Treatment: drugs - dalcetrapib

Experimental: 1 - 

Experimental: 2 - 

Experimental: 3 - 

Experimental: 4 - 


Treatment: drugs: atorvastatin
single dose of atorvastatin on day 1

Treatment: drugs: dalcetrapib
single dose of dalcetrapib on day 1

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Plasma concentration of dalcetrapib</outcome>
      <timepoint>3 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Plasma concentration of atorvastatin</outcome>
      <timepoint>3 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma concentration of atorvastatin metabolites</outcome>
      <timepoint>3 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety: Incidence of adverse events</outcome>
      <timepoint>9 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Healthy volunteers, 18 to 55 years of age, inclusive</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Any concomitant disease or ongoing condition that in the investigator's opinion could
             interfere with the study or could pose an unacceptable risk to the patient

          -  Clinically significant abnormal laboratory values</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>24</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>A single-center, crossover study to evaluate the pharmacokinetics of dalcetrapib and
      atorvastatin from prototype fixed dose combination formulations in healthy volunteers.
      Volunteers will receive a single dose of dalcetrapib with atorvastatin in each of four
      treatment periods.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01363999</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>